Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2014

01-05-2014 | Original Article

Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study

Authors: Hongzan Sun, Jun Xin, Shaomin Zhang, Qiyong Guo, Yueyue Lu, Wei Zhai, Long Zhao, Weiai Peng, Baijun Wang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2014

Login to get access

Abstract

Purpose

To evaluate the concordance among 18F-FDG PET imaging, MR T2-weighted (T2-W) imaging and apparent diffusion coefficient (ADC) maps with diffusion-weighted (DW) imaging in cervical cancer using hybrid whole-body PET/MR.

Methods

This study prospectively included 35 patients with cervical cancer who underwent pretreatment 18F-FDG PET/MR imaging. 18F-FDG PET and MR images were fused using standard software. The percent of the maximum standardized uptake values (SUVmax) was used to contour tumours on PET images, and volumes were calculated automatically. Tumour volumes measured on T2-W and DW images were calculated with standard techniques of tumour area multiplied by the slice profile. Parametric statistics were used for data analysis.

Results

FDG PET tumour volumes calculated using SUVmax (14.30 ± 4.70) and T2-W imaging volume (33.81 ± 27.32 cm3) were similar (P > 0.05) at 35 % and 40 % of SUVmax (32.91 ± 18.90 cm3 and 27.56 ± 17.19 cm3 respectively) and significantly correlated (P < 0.001; r = 0.735 and 0.766). The mean DW volume was 30.48 ± 22.41 cm3. DW volumes were not significantly different from FDG PET volumes at either 35 % SUVmax or 40 % SUVmax or from T2-W imaging volumes (P > 0.05). PET subvolumes with increasing SUVmax cut-off percentage showed an inverse change in mean ADC values on DW imaging (P < 0.001, ANOVA).

Conclusion

Hybrid PET/MR showed strong volume concordance between FDG PET, and T2-W and DW imaging in cervical cancer. Cut-off at 35 % or 40 % of SUVmax is recommended for 18F-FDG PET/MR SUV-based tumour volume estimation. The linear tumour subvolume concordance between FDG PET and DW imaging demonstrates individual regional concordance of metabolic activity and cell density.
Literature
1.
2.
Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236–41.PubMedCrossRef
3.
Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738–44.PubMedCrossRef
4.
Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology. 2013;266:717–40.PubMedCrossRef
5.
Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353–9.PubMedCrossRef
6.
Upasani MN, Mahantshetty UM, Rangarajan V, Purandare N, Merchant N, Thakur M, et al. 18-fluoro-deoxy-glucose positron emission tomography with computed tomography-based gross tumor volume estimation and validation with magnetic resonance imaging for locally advanced cervical cancers. Int J Gynecol Cancer. 2012;22:1031–6.PubMedCrossRef
7.
Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol. 2003;45:208–13.PubMedCrossRef
8.
McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA. Diffusion-weighted MRI in cervical cancer. Eur Radiol. 2008;18:1058–64.PubMedCrossRef
9.
Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36:200–8.PubMedCrossRef
10.
Olsen JR, Esthappan J, DeWees T, Narra VR, Dehdashti F, Siegel BA, et al. Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. J Magn Reson Imaging. 2013;37:431–4.PubMedCentralPubMedCrossRef
11.
Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.PubMedCrossRef
12.
Zaidi H, Ojha N, Morich M, Griesmer J, Hu Z, Maniawski P, et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol. 2011;56:3091–106.PubMedCrossRef
13.
Jung DC, Ju W, Choi HJ, Kang S, Park S, Yoo CW, et al. The validity of tumour diameter assessed by magnetic resonance imaging and gross specimen with regard to tumour volume in cervical cancer patients. Eur J Cancer. 2008;44:1524–8.PubMedCrossRef
14.
Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;52:14–22.PubMedCrossRef
15.
King AD, Ahuja AT, Yeung DK, Fong DK, Lee YY, Lei KI, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology. 2007;245:806–13.PubMedCrossRef
16.
17.
Ma DJ, Zhu JM, Grigsby PW. Tumor volume discrepancies between FDG-PET and MRI for cervical cancer. Radiother Oncol. 2011;98:139–42.PubMedCrossRef
18.
Schramm G, Langner J, Hofheinz F, Petr J, Beuthien-Baumann B, Platzek I, et al. Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction. MAGMA. 2013;26:115–26.PubMedCentralPubMedCrossRef
19.
Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMed
20.
Lucignani G. SUV and segmentation: pressing challenges in tumour assessment and treatment. Eur J Nucl Med Mol Imaging. 2009;36:715–20.PubMedCrossRef
21.
Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5:220–33.PubMedCrossRef
22.
Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25:4104–9.PubMedCrossRef
23.
Nakamura K, Joja I, Kodama J, Hongo A, Hiramatsu Y. Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer. Eur J Nucl Med Mol Imaging. 2012;39:283–90.PubMedCrossRef
24.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.PubMedCrossRef
25.
Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839–46.PubMedCrossRef
26.
Heusch P, Buchbender C, Kohler J, Nensa F, Beiderwellen K, Kuhl H, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Rofo. 2013;185:1056–62.PubMedCrossRef
Metadata
Title
Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study
Authors
Hongzan Sun
Jun Xin
Shaomin Zhang
Qiyong Guo
Yueyue Lu
Wei Zhai
Long Zhao
Weiai Peng
Baijun Wang
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2668-4

Other articles of this Issue 5/2014

European Journal of Nuclear Medicine and Molecular Imaging 5/2014 Go to the issue

Original Article

The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients

Original Article

Association between left ventricular regional sympathetic denervation and mechanical dyssynchrony in phase analysis: a cardiac CZT study

Original Article

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

Editorial Commentary

Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours

Original Article

Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma

Original Article

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours